Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity.

Biomedicines · 2022 · PMC8945229 · PMID 35327415

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ENT-A013-treated cells showed a trend of increased axonal length; however, this difference was not significant compared to the NGF-deprived group ( Figure S3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.